Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
To characterize the demographic, clinicopathological, treatment response, and complication profile of patients with lupus nephritis(LN) of the the population from Andhra Pradesh , Southern part of India
This retrospective analysis included 57 SLE LN cases. Demographic data, histopathological classes (based on 54 biopsies), immunofluorescence (IF) findings (48 cases), treatment response at various follow- up periods (6-36 months), and recorded complications were analysed. Severe lupus nephritis cases were treated as per the NIH protocol, with induction therapy consisting of intravenous methylprednisolone (30 mg/kg body weight) administered for three consecutive doses at initiation, followed by monthly intravenous cyclophosphamide pulses for six months. Maintenance therapy included mycophenolate mofetil and a tapering dose of oral prednisolone, along with other supportive medications.
In these 57 cases mean age was 30.6yrs (SD:10yrs; Range 15 to 54 is 39), Female – to- male ratio was 10.4:1.
Histopathology: The most common classes were Class IV (Diffuse LN) and Class V (Membranous LN), each accounting for 25.92% of cases. Class III for 24.07%, Mixed Classes (III + IV and IV + V) accounted for 5.55% each, Class II for 9.25%and Class I and VI for 1.85% each.
Immunofluorescence: A “ full house” pattern was observed in 39.5% of cases. Lambda light chain deposition (54.1% at 3+ and above) was more frequent than Kappa (41.6% at 3+ and above). IgG was the most common immunoglobulin deposited (72.9% at 3+ and above) and IgM (4.1% at 3+ and above). IgA was negative in 20.8% of cases. C1q (35.4% at 3+ and above), C3c (25% at 3+ and above).
Response to treatment: Excluded cases who lost follow up (15 cases) and cases whose follow up was less than 6 months (6 cases). Out of remaining 36 patients Complete remission (CR) seen in 38.2%, Partial remission (PR) in 50%, no response (NR) in 8.33%, death in 5.55% cases in first 6 months. Out of 25 follow up cases in 12 months CR occurred in 48% cases, PR in 32%, NR in 12%, relapsein 2.8%. Out of 17 follow up cases in 18 months CR occurred in 58.8% cases, PRin 29.4%, relapse in 11.7%. Out of 11 follow up cases in 24 months CR occurred in 72% cases, PR in 18.8%, NR in 9.09%. Out of 5 follow up cases in 30 months CR occurred in 80% cases, relapse in 20%. Out of 3 follow up cases in 36 months CR occurred in 66.6% cases, relapse in 33.3%.
Complications: The most frequent complication were Leucopenia (15.7%), and Herpes (10.5%). UTI (5.26%); Tuberculosis and candidiasis (3.5% each); Toxoplasmosis, thrombocytopenia, B/L AVN and septic arthritis in (1.7% each).
The LN cohort in southern part of India predominantly presented with Diffuse proliferative and membranous histopathological classes(class IV and V), demonstrating a significant female predominance. Immunofluorescence frequently showed IgG, C1q and a dominant lambda light chain deposition. Early treatment showed promising complete remission rates and CR rate increased with duration of treatment, though a considerable proportion experienced relapse during extended follow-up, highlighting the need for vigilant monitoring and tailored maintenance therapy. Leucopenia and Herpes infections were the most common adverse events.
